Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health, today announces that the US Food and Drug Administration (“FDA”) has granted over the counter sale (“OTC”) Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction (“ED”) as a De Novo Medical Device.
Futura Medical has reported phase 3 data on its topical erectile dysfunction treatment MED3000, teeing it up to file for FDA approval of the therapy as an over-the-counter medicine by the end of the month.
GUILDFORD, England--(BUSINESS WIRE)--Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, “FM71” for MED3000, an investigational therapy for the treatment of erectile dysfunction (“ED”).
Futura Medical PLC (AIM:FUM) appointed consumer healthcare products veteran Jeff Needham to the board as a non-executive director.
ST. PETERSBURG, RUSSIA, September 21, 2021 /EINPresswire.com/ -- Futura Medical, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, has partnered with OCT Clinical to run its FM71 clinical study for MED3000 in erectile dysfunction in 4 countries: Bulgaria, Poland, Georgia and the USA. The companies have already reported the first patient entering the screening in Georgia earlier this week.